Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: Preliminary results

Medical Science Monitor

Volumn 19, Issue 1, 2013, Pages 852-857

  Mesples, Alejandro ^a   Majeed, Nasir ^b   Zhang, Yun ^b   Xiang, Hu ^a  

^a Diabetes Education and Research   (Argentina)

^b Shenzhen Beike Cell Engineering Research Institution Shenzhen   (China)

Author keywords

Bone marrow stem cells; Bone marrow transplantation; Type 1 diabetes

Indexed keywords

C PEPTIDE; CELL ANTIBODY; GLUCOSE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; LIOTHYRONINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; CASE REPORT; CHILD; COMATOSE PATIENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABILITY; LIVER BIOPSY; NAUSEA; OUTCOME ASSESSMENT; POLYDIPSIA; POLYURIA; PRESCHOOL CHILD; SCHOOL CHILD; SKIN BRUISING;

ADULT STEM CELLS; BLOOD GLUCOSE; BONE MARROW TRANSPLANTATION; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMOGLOBINS; HUMANS; IMMUNOTHERAPY; INSULIN ANTIBODIES; ISLETS OF LANGERHANS; RECOMBINANT PROTEINS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84885898828     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889525     Document Type: Article

References (33)

1. Gianani R, Campbell-Thompson M, Sarkar SA et al: Dimorphic histopathology of long-standing child- hood-onset diabetes. Diabetologia, 2010; 53: 690-98
2. Madsbad S, Krarup T, Regeur L et al: Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. Acta Endocrinologica, 1980; 95: 359-63
3. Sue M, Yoshihara A, Otani T et al: Characteristics of fulminant type 1 diabetes mellitus. Med Sci Monit, 2008; 14(10): CS97-101
4. Zhao Y, Huang Z, Qi M et al: Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunol Lett, 2007; 108: 78-87
5. Uccelli A, Moretta L, Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol, 2008; 8: 726-36
6. Bluestone JA, Tang Q, Sedwick CE: T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol, 2008; 28: 677-84
7. Alonso N, Soldevila B, Sanmarti A et al: Regulatory T cells in diabetes and gastritis. Autoimmun Rev, 2009; 8: 659-62
8. Haller MJ, Viener HL, Wasserfall C et al: Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol, 2008; 36: 710-15
9. Brissova M, Shostak A, Shiota M et al: Pancreatic islet production of vascular endothelial growth factor - a is essential for islet vascularization, revascularization, and function. Diabetes, 2006; 55: 2974-85
10. Brissova M, Powers AC: Revascularization of transplanted islets: can it be improved? Diabetes, 2008; 57: 2269-71
11. Virtanen I, Banerjee M, Palgi J et al: Blood vessels of human islets of Langerhans are surrounded by a double basement membrane. Diabetologia, 2008; 51: 1181-91
12. Kragl M, Lammert E: Basement membrane in pancreatic islet function. Adv Exp Med Biol, 2010; 654: 217-34
13. Irving-Rodgers HF, Ziolkowski AF, Parish CR et al: Molecular composition of the peri-islet basement membrane in NOD mice: a barrier against destructive insulitis. Diabetologia, 2008; 51: 1680-88
14. Zhao Y, Jiang Z, Zhao T et al: Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med, 2012; 10: 3
15. Wild S, Roglic G, Green A et al: Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care, 2004; 27: 1047-53
16. Onkamo P, Väänänen S, Karvonen M, Tuomilehto J: Worldwide increase in incidence of Type I diabetes - the analysis of the data on published incidence trends. Diabetologia, 1999; 42: 1395-403
17. Achenbach P, Bonifacio E, Koczwara K, Ziegler A-G: Natural History of Type 1 Diabetes. Diabetes, 2005; 54 (Suppl.2): S25-S31
18. Palmer JP: C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev, 2009; 25(4): 325-28
19. Abdi R, Fiorina P, Adra CN et al: Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes, 2008; 57: 1759-67
20. Aguayo-Mazzucato C, Bonner-Weir S: Stem cell therapy for type 1 diabetes mellitus. Nat Rev Endocrinol, 2010; 6: 139-48
21. Zhao Y, Glesne D, Huberman E: A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Nat Acad Sci USA, 2003; 100: 2426-31
22. Zhao Y, Lin B, Dingeldein M et al: New type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes. Transl Res, 2010; 155: 211-16
23. Zhou Q, Brown J, Kanarek A et al: In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature, 2008; 455: 627-32
24. Petrovsky N: Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus. Nat Rev Endocrinol, 2010; 6: 131-38
25. Pittenger MF, MacKay AM, Beck SC et al: Multilineage potential of adult human mesenchymal stem cells. Science, 1999; 284: 143-47
26. Nauta AJ, Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood, 2007; 110(10): 3499-506
27. Habib H, Halawa T, Atta H: Therapeutic applications of mesenchymal stroma cells in pediatric diseases: Current aspects and future perspectives. Med Sci Monit, 2011; 17(11): RA233-39
28. Rasmusson I: Immune modulation by mesenchymal stem cells. Exp Cell Res, 2006; 312: 2169-79
29. Le Blanc K, Tammik C, Rosendahl K et al: HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 2003; 31: 890-96
30. Leblanc K, Ringden O: Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med, 2007; 262: 509-25
31. Di Nicola M, Carlo-Stella C, Magni M et al: Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. Blood, 2002; 99: 3838-43
32. Tse WT, Pendleton JD, Beyer WM et al: Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 2003; 75: 389-97
33. LeBlanc K, Tammik L, Sundberg B et al: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol, 2003; 57: 11-20